Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
المؤلفون المشاركون
Merx, K.
Barreto Miranda, Manuel
Kellermann, Lenka
Mahlknecht, Ulrich
Lange, Oliver
Gonnermann, Michael
Hofheinz, Ralf-Dieter
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-01-28
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced or metastatic esophagogastric cancer.
Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab.
Earlier published data about patients treated outside clinical studies showed a relatively low rate of HER2-testing and insufficient test quality.
A total of 2,808 patients retrospectively documented in Therapiemonitor ® from 2006 to 2013 were analysed regarding treatment intensity and trends in used drugs.
Data on HER2-testing and therapies were analysed in two cohorts documented in 2010 and 2011 (1) compared to 2012 and 2013 (2).
Treatment intensity increased: 49.3% of patients received at least a triplet in 2013 compared to 10.1% in 2006.
In cohort 2 HER2 expression was tested in 79.1% of the cases.
Still, in 26.9% testing was not done as requested by guidelines.
Good performance status, multiple metastases, age ≤ 65 years, the objective “to prevent progression,” good cognitive capabilities, estimated good compliance, and social integration positively influenced the probability of HER2-testing; comorbidities negatively affected it.
Usage of the combination of fluoropyrimidines and cisplatin with trastuzumab declined from 67% in cohort 1 to 50% in cohort 2.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Merx, K.& Barreto Miranda, Manuel& Kellermann, Lenka& Mahlknecht, Ulrich& Lange, Oliver& Gonnermann, Michael…[et al.]. 2016. Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany. Gastroenterology Research and Practice،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1104577
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Merx, K.…[et al.]. Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany. Gastroenterology Research and Practice Vol. 2016, no. 2016 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1104577
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Merx, K.& Barreto Miranda, Manuel& Kellermann, Lenka& Mahlknecht, Ulrich& Lange, Oliver& Gonnermann, Michael…[et al.]. Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany. Gastroenterology Research and Practice. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1104577
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1104577
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر